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INFLUENZA VIRUS AND PROTEOLYTIC BACTERIA CO-INFECTION IN RESPIRATORY TRACT FROM
INDIVIDUALS PRESENTING RESPIRATORY MANIFESTATIONS
Dalva Assunção Portari MANCINI(1), Rosely C. Barbosa ALVES(1), Rita Maria Zucatelli MENDONÇA(1), Nancy J. BELLEI(2), Emerson CARRARO(2),
Antonia M.O. MACHADO(3), José Ricardo PINTO(1) & Jorge MANCINI FILHO(4)
SUMMARY
A role for proteolytic bacteria in the exacerbation of influenza virus has been shown in natural hosts such as pigs and humans.
Four hundred seven samples were collected from the respiratory tract of individuals presenting clinical manifestations, during
influenza season (2003-2005) in São Paulo City. The aim of this study was to evaluate the incidence of determined bacteria co-
infecting virus in human respiratory tract. Tests, such as bacteriological, immunofluorescence (IF), RT/PCR and hemagglutination
(HA) were used for bacterial and viral investigation. Thirty seven (9.09%) positive for influenza virus were screened by IF. The
RT/PCR confirmed the presence of influenza virus in these samples. Bacterial and agar casein tests demonstrated that 18 (48.64%)
individuals were infected with proteolytic bacteria such as Staphylococcus spp., Streptococcus spp. and Pseudomonas spp. Among
these samples, 13 (35.13%) were co-infected with influenza A virus. Influenza type B, co-infecting bacteria were found in five
(13.51%) samples. In vitro the S. aureus protease increased the influenza HA titer after contact for 30 min at 25 ºC. Results
revealed the occurrence of co-infection with proteolytic bacteria and influenza in the evaluated individuals. This finding corroborates
that virus versus bacteria synergism could be able to potentiate respiratory infection, increasing damage to hosts.
KEYWORDS: Influenza; Proteolytic bacteria; Co-infection; Respiratory tract.
INTRODUCTION
Virus-bacteria association3,17,18 infections has been reported to be
one of the major causes of severe influenza pneumonia in human,
possibly due to the synergistic effect of these microorganisms during
the respiratory tract invasion. On the one hand, the influenza virus
requires an enzymatic action to achieve the hemagglutinin molecule
cleavage that increases its infectivity in host cells; this action is provided
by the bacterial protease. On the other hand, the influenza virus can
promote bacteria adherence on the host cells, where the bacterial
adhesins are able to act when the cells are infected by this virus16.
The interaction between bacteria and influenza virus has been
studied in vitro as well as in vivo, using different proteases such as
urokinase, kallikrein, plasmin and thrombin in comparison with the
bacterial protease (staphylokinase and streptokinase) and measuring
influenza virus replication. Results indicated that interaction of
extracellular proteases with the HA may activate viral infection in both
experimental and in natural situations17. Even with the uncleaved
Hemagglutination (HA), the influenza virus could become infectious
through the host cell endoproteases, sometimes induced by enzymatic
activation13.
In addition to the lack of understanding regarding the association
mechanism of bacteria and influenza virus, some studies suggest an
enhancement of respiratory infections in this situation3,5,16.
Many microorganisms may represent an important source of
proteases capable of a proteolytic activation of influenza virus.
Staphylococcus aureus, Streptococcus pneumoniae and S. pyogenes
are the most common bacteria in respiratory flora, that also includes
Pseudomonas aeruginosa and Stenotrophomonas maltophilia; the latter
two species of microorganisms coming from environmental sources17.
In our previous study, an increase of influenza infectivity was observed
when these virus isolate samples, collected from natural hosts, were
co-infected with S. maltophilia10.
In the present study, the co-infection influenza virus proteolytic
bacteria in samples obtained from individuals presenting respiratory
symptoms, including hospitalized patients presenting a situation of
immune depression was studied. The ability of these bacterial species
to exacerbate influenza in humans, under these conditions, has been
investigated. Since there is a lack of these informations in Brazil, our
objective was to verify the interaction influenza virus proteolytic
bacteria in our country. However, it was not our objective, the evaluation
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of the clinical manifestation exacerbations as answers to this co-
infection.
MATERIAL AND METHODS
Microorganism isolation (12): A total of 407 nasal washes were
collected with sterile PBS from patients (kidney transplanted), health
care workers and general population with respiratory manifestation.
Subjects ranged from 12 to 30 years old, were attended at the
Universidade Federal de São Paulo (UNIFESP) Hospital, between 2003
and 2005. Samples were provided to both the laboratories of Virology
and Bacteriology, and the techniques were performed as follows:
1. Virological tests
1.1. Immunofluorescence technique(18): The 407 samples, as
referred above, were clarified by centrifugation at 2,000g for 10 min
before screening for influenza positivity by immunofluorescence
technique. This was performed initially by addition of mucolytic
solution to these samples, followed by centrifugation at 300-500g, and
incubation for 10 min at room temperature, for fixation. After this,
monoclonal antibodies to influenza A and B types and parainfluenza
viruses, conjugated with fluorescein isothiocyanate, were added on a
Light Diagnostic Simulfluor Respiratory Screen (Biotrin®). After 15
min at 37 °C (humidity chamber) the smear samples were washed
with PBS (Tween) three times, for 10 sec each, and left to dry. Material
was then observed by immunofluorescence microscopy (Olympus -
BX51). Among the prepared samples, a standard influenza sample was
included to compare the positive antigen and fluorescent influenza
antibody mashes, during the microscopic examination. All samples
that presented this feature, revealing fluorescence with a brilliant -
green color, are considered to be the influenza virus. The other samples,
considered not to be influenza antibody reagent, present a red color,
due to the Blue Evans stain used for negative test confirmation.
1.2. Chain Reaction (RT/PCR) technique:
1.2.1. RNA viral extraction (4): Viral RNA is extracted from
screened influenza isolate samples technique utilizing a mixing of 250
µL of the sample and 750 µL of the Trizol reagent (Invitrogen®) and
kept at room temperature for five min with addition of the 200 µL
Chloroform (Merck®). The samples are mixed by vortexing for 15 sec
and kept at room temperature for five min, after this they are centrifuged
at 15,294g for 15 min at 4 °C. Four hundred microliters of the
supernatant are removed avoiding the interfase and 500 µL of the
isopropanol (Synth®), it is then mixed by vortexing for five sec. These
samples are centrifuged at 15,294 g for five min at 4 °C and discarding
the supernatant. To this pellet, 1,000 µL of ethanol (75%) (Synth®) are
added, and mixed gently following of centrifugation at 15,294 g for 10
min at 4 °C and discarding the supernatant.
Finally, 20 µL of distilled water DNAse, RNAse free are added
and incubated at 50 °C for 10 min. This material is stored at -70 °C
until performance of the reverse transcription technique.
1.2.2. Reverse transcription/PCR (6): Five microliters of viral
RNA are added to 1.0 µL of primer PcDNA (flu) and 1.0 µL of primer
REV, 1.0 µL of 10 mM dNTP mix and 4.0 µL of sterile distilled water.
The reaction after heating at 65 °C for five min is quickly chilled on
ice followed by adding 4.0 µL of 5X First Strand Buffer (Invitrogen®),
2.0 µL of 0.1M DTT (Invitrogen®), 1.0 µL of Rnase Out Ribonuclease
Inhibitor (Invitrogen®), and incubated at 37 °C for two min. Next, it is
added 1.0 µL (200 units) of RT (M-MLVRT-Invitrogen®), mixed by
pipetting gently, incubated at 37 °C for 50 min and the reaction was
inactivated by heating at 70 °C for 15 min. The PCR product, is the
viral cDNA that should be stored at -70 °C.
PCR Reaction for Amplification: Five microliters of cDNA are
amplified in a volume of 50.0 µL containing 5.0 µL PCR buffer 10X
20 mM Tris-HCl pH 8.4, 500 mM KCl, 1.5 µL 50 mM MgCl2, 1.0 µL
10 mM dNTP, 35.1 µL H2O DEPEC, 1.0 µL of primer PcDNA
(- ; FLU), 1.0 µL of primer REV(+; Flu) and 0.4 µL (5U/µL) Taq
polymerase. This reaction mixture is warmed by Thermal Cycler (Bio-
Rad®) at 94 °C for 45 sec and 35 cycles of: 45 sec at 94 °C; 30 sec at 55
°C ;1.3 min at 72 °C, and 72 °C for 10 min. Finally, it is left at 4 °C for
indeterminate time. The PCR amplified product is analyzed by 2.0%
agarose gel (Sygma®) electrophoretic run 60V and bands stained with
0.5 µg/mL ethidium bromide, and documented by Fluorescent Table
(Vilber-Lourmat®) and photographed by digital camera (Sony®).
Influenza virus type A (H3N2), used as standard, will confirm the
samples positivity through the bands revealed with 189 bp from the
primers corresponding to no structural antigen{NS1} gene fragment
of the influenza virus.
Primer PcDNA Sequence (5’ to 3’): AAG GGC TTT CAC CGA
AGA GG
Primer REV Sequence (5’ to 3’): CCC ATT CTC ATT ACT GCT
TC
1.3. Hemagglutination (HA) Test (9): Laboratory cell-adapted
strain of Influenza virus A/SP/1/91 (H3N2) after contact, for 60 min at
25 °C, with bacterial protease samples, performed the virus
hemagglutination titer, which is determined at room temperature in a
microtiter system. Serial two fold dilutions of virus (25 µL) in
phosphate-buffered pH 7.2 are mixed with 25 µL of a 0.5% suspension
of rooster red blood cells. Hemagglutination titers are determined after
one hour, unless otherwise stated, and are expressed as the reciprocal
of the maximum dilution of virus that causes complete agglutination.
1.4. Cytopathic effects in cell culture (7):
1.4.1. Infection of cell culture by Influenza virus in the presence
of bacterial protease: Laboratory cell-adapted strain of Influenza virus
type A/SP/1/91 (H3N2) is used to infect monolayers of MDCK cells. In
twelve wells of plastic plaque (Falcon, USA) with cell culture, it was
inoculated 0.1 mL of each influenza virus dilution at 10-1 to 10-4
previously contacted with bacterial protease (0.1 mL) for 60 min at
25 °C. The plaque with infected cells is left for 30 min at 33 °C, and
then completed with the Leibovitz-15 medium. Controls such as
influenza virus replication in absence or presence of trypsin
(30 µg/mL) and normal cells are performed likewise the experimental
test. Four wells are used for each test: experiment and controls. These
test results hold on increase of the virus influenza infectivity titer,
such as by cytopathic effect (CPE) as well by HAU, both detected
after seven days of the virus inoculation, which is the end test.
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2. Bacterial tests (12)
2.1. Bacterial cultivation and identification: From the total
sampling of the 407 collected individuals, thirty seven samples screened
by immunofluorescence as influenza positive were chosen for bacteria
detection through the cultures in Tryptic Soy Broth (TSB) for 18-24 h
at 35 °C - 37 °C. Samples that presented medium opacity, after this
time, were submitted to the identification assay. For this, the cultured
bacteria was dropped on glass smears and stained by the Gram technique
and then visualized by optic microscopy. The microorganisms, of both
coccoids and bacillar morphologies [being Gram (+) or (-)], were
screened by biochemical methods. For Gram positive microorganism
identification by catalase test, a serology test was employed using the
Staphy Test commercial kit (Probac®), to identify the Staphylococcus
aureus and negative coagulase. This positivity test is observed through
the agglutination of the sheep blood sensitized by hemolysin and
fibrinogen. Referring to negative test result, that lead to suggest to be
Staphylococcus negative coagulase concerning Streptococcus
identification, plaques (Petri) with sheep blood agar (5%) were prepared
to differentiate hemolysis types. The material, previously isolated with
a coccoid form, as verified by microscopy, was cultured on these plates
and Optochine discs added (5 µg) (Probac®) before incubating in CO2
atmosphere (range 5 - 10%) for 24 h at 37 °C. After this time, the
bacterial culture that presented halo ≥14 mm around these discs may
be considered as S. pneumoniae, and those which demonstrated a green
color with halos are identified as S. viridans.
Plaques of E.M.B: Agar were used for cultivation of the Gram
negative microorganism isolated and identified through biochemical
assays. The Pseudomonas spp. can be suspected by betalactams
antibiotic resistance.
2.2. Protease Test-Agar Casein Assay (3): Bacterial isolates
cultured in Tryptic Soy Broth (TSB) were centrifuged at 12,000g for
15 min at 4 °C and filtered through a Millipore 0.45 µm pore-diameter
syringe filter. Clarified supernatant was tested for proteolytic activity
on casein agar plates. Casein agar plates consisted of 25 mM Tris (pH
7.2), 150 mM NaCl, 0.6% casein (Sigma technical grade) and 1% Bacto
Agar (Difco®). Aliquots (10 µL) of culture supernatants are placed in 3
mm diameter wells cut in the casein agar and incubated at 37 °C for
18h. The plates are overlaid with 3% acetic acid, and proteolytic
activities are noted as a zone of clearing around the sample well. Trypsin
(1 µg/mL) was used as a positive control standard. Caseinolytic activity
of the proteolytic bacteria, also relative to trypsin used as a control,
was determined by measuring the diameter of the proteolytic zones
around each well.
RESULTS
Through the virological tests, among of the 407 samples collected
from individuals presenting respiratory manifestations, thirty seven
(9.09%) samples were chosen that had been previously demonstrated as
influenza virus positive by immunofluorescence, in whose samples the
parainfluenza was not detected. These samples were identified as being
25 (67.56%) samples of type A and 12 (32.43%) of type B. The fluorescent
positive influenza sample is shown in Fig. 2. The RT/PCR technique
characterized the influenza virus in some samples previously screened
for this virus. The electrophoretic bands revealed that the isolated
influenza virus strains were compatible with standard influenza A/SP/1/
91 (H3N2). A PcDNA(flu) primer was used to amplify a 189 bp fragment
of the non-structural (NS-1) gene of influenza virus in Fig. 3.
Of the eighteen samples (48.64%) presenting Staphylococcus
negative coagulase, Staphylococcus aureus, Streptococcus viridans,
Streptococcus pneumoniae and Pseudomonas aeruginosa that were
obtained from thirteen (35.13%) influenza types A and five (13.31%)
B samples and characterized by the bacteriological tests recommended
for this type of investigation (Table 1 and Fig. 1). The Agar Casein test
showed three samples of these bacteria isolates with protease action,
as verified by the zone of clearing around each bacteria sample well.
Trypsin represents the proteolytic action control. The Staphylococcus
negative coagulase (isolated) and S. negative coagulase from ATCC
represent the lack of the proteolytic action (Fig. 4).
Using laboratory cell-adapted strains of influenza virus A/SP/1/91
(H3N2), contacted or not previously with bacteria proteases from
Pseudomonas aeruginosa (sample 68); Staphylococcus aureus (sample
158); Streptococcus viridans (sample 342); Streptococcus pneumoniae
(samples 344 and 356), the increase in infection by this virus, as in
MDCK cells, was observed by their cytopathic effect (CPE) as well as
by their hemagglutinin titers. Trypsin was used to demonstrate
enzymatic action on the influenza hemagglutin cleavage, with viral
exacerbation. These results are demonstrated in Table 2 and Fig. 5.
Bacteria such as Pseudomonas aeruginosa (sample 68) co-infecting
influenza samples, as well as in combination with cell-adapted influenza
A (H3N2) are represented in Fig. 6a and 6b.
DISCUSSION AND CONCLUSION
Bacteriological and Virological tests demonstrated that the samples
collected by nasal wash from individuals presenting respiratory
manifestations, revealed bacteria and influenza virus presence
concomitantly. The influenza type A was more incident than type B,
as well the Staphylococcus reached the higher percentage, in these
evaluated samples.
Fig. 1 - Percentage of Staphylococcus spp., Streptococcus viridans, S. pneumoniae and
Pseudomonas spp. co-infecting with influenza A and B viruses in nasal washes from patients
exhibiting manifestations of respiratory ailment.
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Proteolytic bacteria, such as Pseudomonas spp., Staphylococcus
spp. and Streptococcus spp., were identified in these samples. The
protease action of these bacteria was demonstrated by the assay
performed with cell-adapted influenza virus A (H3N2) that was
exacerbated through contact with the bacteria isolates. Influenza
Table 1
Relation of the detection of influenza virus and bacteria in nasal washes
collected from individuals presenting respiratory manifestations
Tests
Screened Imunofluorescence Bacteriological identification
samples Influenza type Microorganism
A B
1 + - N
2 + - Staphylococcus negative
coagulase
5 - + Streptococcus viridans
7 - + Streptococcus viridans
16 + - N
24 + - N
25 - + N
27 - + N
28 + - N
29 - + Staphylococcus aureus
30 + - Staphylococcus aureus
36 - + N
38 + - N
39 - + N
40 + - N
68 + - Pseudomonas aeruginosa
116 - + Staphylococcus negative
coagulase
130 - + N
142 + - Staphylococcus negative
coagulase
147 + - Staphylococcus negative
coagulase
149 - + N
151 - + N
152 + - Staphylococcus aureus
155 - + Staphylococcus negative
coagulase
156 + - N
158 + - Staphylococcus aureus
159 + - N
327 + - Staphylococcus aureus
340 + - N
342 + - Streptococcus viridans
344 + - Streptococcus pneumoniae
346 + - N
356 + - Streptococcus pneumoniae
358 + - Staphylococcus aureus
366 + - N
367 + - Streptococcus viridans
375 + - N
37  25 (67.56%) 12 (32.43%) 18 (48.64%)
N - Negative.
Fig. 2 - Immunofluorescence micrograph of the influenza virus in nasal washes from patients
exhibiting symptoms of respiratory ailment. - Green = Positive Antibody reaction to the
Influenza virus; - Red = Negative Antibody reaction to the Influenza virus.
Fig. 3 - Characterization by RT/PCR of the influenza virus in nasal washes from patients
presenting respiratory ailments manifestations. Lane 3 - Sample # 68; Lane 4 - Sample #
342; Lane 5 - Influenza virus type A(H3N2); Lane 6 - Distilled water.
Fig. 4 - Agar-Casein Test - Protease-positive Bacteria co-infecting samples of influenza virus
isolate. #68 - Pseudomonas aeruginosa - Protease Positive; #342 - Streptococcus viridans -
Protease Positive; #344 - Streptococcus pneumoniae - Protease Positive; #2 - Staphylococcus
negative coagulase; #116 - Staphylococcus negative coagulase; ATCC/SNC - Protease
Negative Control; Trypsin - Protease Positive Control.
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infectious and hemagglutinin titers were amplified by co-infecting with
proteolytic bacteria, compared with trypsin presence or absent in these
tests. Then, considering this finding with regards to exacerbation of
the influenza virus infectivity by bacterial protease, observed in vitro,
lead to suggest the damage that this co-infection causes to the hosts.
Thus, observations since the early eighties by authors such as
TASHIRO et al., 1987, BULGAKOVA et al., 1987, demonstrate these
bacteria as being responsible for fatal disease in mice lungs, when co-
infected with influenza virus. These studies were continued over twenty
decades11, demonstrating the lethal synergism between influenza virus
and Streptococcus pneumoniae that led to 100% of mortality in mice
used as an experimental model. This finding has been related not only
in animal models; a synergism between bacteria-influenza virus has
been reported, and also observed in children with pneumococcal
pneumonia that preceded influenza infection14 at the Centers of Disease
Control, in Atlanta, USA. Once again, hospitalized children with
Community Acquired Pneumoniae (CAP), provoked by influenza
infection concomitant with Streptococcus pneumoniae, were evaluated
by PONS-CATALANO et al., 2003. Recently, BEADLING & SLIFKA,
2004, reported that bacterial sepsis was a leading cause of death in the
United States, where the mechanisms of lethal synergism between
bacteria and influenza virus are responsible for the sepsis in these
hospitalized individuals. Authors suggest that preventive measures,
including vaccination against influenza and aggressive anti-microbial
therapy, early on the course of infection, may reduce the morbidity
and mortality by sepsis.
Based on our data and the other reports cited, it may be concluded
that co-infection between these microorganisms exacerbates respiratory
infections. This situation may be aggravated in hospitalized individuals
with immune depression, such as in some patients evaluated in this
work. The clinical exacerbations had been not investigated in this work.
Even so, this could occur among the evaluated subjects. Therefore,
beyond the cited measurements suggested for this preventive control,
it is important to currently investigate the most frequent bacterial
species that could be associated with influenza virus infection, in the
hospital environment, to offer the appropriate medical action against
these infectious agents.
About this issue, natural antioxidants from spice extracts are being
used as anti-microbials in these bacterial isolates, following our
previous findings on the anti-viral action of phenolic compounds,
present in natural antioxidants, including the rosemary spice8. In
addition, inhibitors against bacterial proteinase are being recommended
to ameliorate the anti-pathological processes, with reduction of growth
rate of the invading organism, allowing the host defense response to
be re-established20. These findings require further studies, to investigate
the synergism between cell endoproteases and microbial proteases in
the cleavage of influenza hemagglutinins, as well the cell-adhesin
bacteria, favored by the influenza virus, which certainly could potentiate
the clinical manifestations of respiratory infections.
The first step of this study had been lead to investigate the incidence
of co-infection between virus and proteolytic bacteria, with stand out
the influenza infection exacerbation, and the next step will be expended
with regards to the bacterial infection exacerbation, under viral co-
infection conditions.
Table 2
Cell-adapted influenza type A (H3N2) strain infectivity (TCID50%) and
hemagglutining titer exacerbations by co-infection with proteolytic bacteria
Dilution
Influenza Influenza Infectivity by CPE Virus
+ Bacteria Sample Control
Protease #68  #342 #344 #356 Trypsin
10-1 70% 100% 100% 100% 75%
10-2 65% 70% 70% 70% 60%
10-3 60% 60% 65% 65% 40%
10-4 40% 50% 50% 60% 30%
10-5 30% 40% 40% 40% 10%
TCID50 10
3.4 103.7 104.0 104.0 102.8
 TITER (HAU) 25 28.8  36 38  8
CPE - Cytopathic Effect; TCID50 - Tissue Cell Infectious Doses; HA -
Hemagglutination; HAU - Hemagglutinating Unit.
Fig. 6 - Electron micrograph of proteolytic bacteria present in influenza samples isolated
from hospitalized patients. a) Sample #68 - Pseudomonas aeruginosa; B = Bacteria; FL =
Flagellum; Magnification = 15,455 X; Scale bar = 100 nm. b) Cell-adapted influenza virus A
(H3N2) in contact with bacteria; B = Bacterium; VP = Viral Particle; FL = Flagellum;
Magnification = 35,089 X; Scale bar = 100 nm.
Fig. 5 - Cytopathic effect of the cell-adapted influenza A virus (H3N2) with and without
protease in MDCK cells. a) - Normal MDCK cells; b) - Influenza X Bacterial Protease; c) -
Influenza X Trypsin; d) Influenza without Protease.
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RESUMO
Vírus influenza e bactéria proteolítica co-infectantes em trato
respiratório de indivíduos com manifestações respiratórias
O papel da bactéria proteolítica na exacerbação do vírus influenza
tem sido demonstrado em hospedeiros naturais como porcos e humanos.
Foram coletadas 407 amostras do trato respiratório de indivíduos
apresentando manifestações clínicas, durante a estação da influenza
(2003-2005) na cidade de São Paulo. Este trabalho teve como objetivo
avaliar a incidência de determinadas bactérias que junto com vírus co-
infectarem o trato respiratório humano. Testes bacteriológicos, e
virológicos como imunofluorescência (IF), RT/PCR e hemaglutinação
(HA) foram usados nas investigações viral e bacteriana. Pelo teste de
IF foram selecionadas trinta e sete (9,09%) amostras positivas para o
vírus influenza. A presença do vírus influenza foi confirmada pela
técnica de RT/PCR. Pelos testes bacteriológicos e do agar caseina,
verificou-se que 18 (48,64%) dos indivíduos foram infectados com
bactérias proteolíticas tais como Staphylococcus spp., Streptococcus
spp. e Pseudomonas spp. Destas amostras, 13 (35,13%) foram co-
infectadas com vírus influenza tipo A, e 5 (13,51%) com influenza
tipo B. No experimento in vitro com influenza e S. aureus, detectou-se
aumento do título hemaglutinante deste vírus, após contacto de 30
min a 25 ºC. Os resultados obtidos revelaram a ocorrência de co-
infecção com bactéria proteolítica e vírus influenza nos indivíduos
avaliados. Estes achados corroboram com a investigação do sinergismo,
entre bactéria e vírus, que poderia ser capaz de potencializar infecção
respiratória, aumentando os riscos aos hospedeiros.
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